Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Rex MD vs Call-On-Doc

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #331

Rex MD

Cost-first shoppers who want men wanting brand-name Wegovy/Zepbound access through a manufacturer direct-pay bridge, not compounded medication.

Visit Rex MD
VS
Grade C · #336

Call-On-Doc

Shoppers who already have insurance covering a branded GLP-1 and want a low-cost consult subscription to get the prescription written.

Visit Call-On-Doc

The verdict

Winner · Rex MDGrade C vs C

Rex MD takes it, leading the Cost-Efficiency Index 56 to 55. Rex MD (a LifeMD brand, historically known for ED telehealth) also runs a real weight-management program, but it is a referral model rather than a compounder: a $75/month Rex MD program fee covers consultation, coaching and labs. Call-On-Doc still earns a CShoppers who already have insurance covering a branded GLP-1 and want a low-cost consult subscription to get the prescription written.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Rex MD.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

28
45

Price Transparency

20
20

Nationwide Access

86
86

Formulation Options

90
53

Clinical Oversight

84
85

Contract Flexibility

55
55

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecRex MDCall-On-Doc
Cost-Efficiency Index56/10055/100
Semaglutide / mo$574/mo (all doses, plus a separate fee, brand-name)Not disclosed
Tirzepatide / mo$424/mo (brand Zepbound, plus a separate fee)Not disclosed
Semaglutide / yr (modeled)$6,888
Tirzepatide / yr (modeled)$5,088
CoverageAll 50 statesAll 50 states
Oral / sublingualYesNo
Brand-name accessYesYes
Rank here#331#336

Rex MD

56/100

Where the value is

  • Genuine FDA-approved brand-name medication (Wegovy, Zepbound, Saxenda) rather than compounded — a different, more regulated tier than most of this list
  • Named medical leadership (Dr. Anthony Puopolo, M.D., Rex MD Affiliated Medical Group) and a LegitScript Certified badge
  • Backed by publicly known parent LifeMD, with an established telehealth track record

The tradeoffs

  • The headline $75 is NOT the medication cost — Wegovy runs an additional $499/mo (any dose) and Zepbound vials an additional $349/mo, both billed separately by the manufacturer, not Rex MD
  • All-in realistic cost is roughly $424-$574/month, far above what a '$75' or even a '$349' headline implies depending on which landing page you see
Visit Rex MD

Full Rex MD review →

Call-On-Doc

55/100

Where the value is

  • LegitScript seal displayed, with 50-state coverage claimed via a state-selection dropdown
  • Low-cost visit subscription tiers ($24.99-$49.99/mo) that include multiple free visits per month, cheaper than most one-off telehealth consult fees
  • Explicitly lets patients use their own insurance at their own pharmacy, which can be dramatically cheaper than a self-pay compounded-GLP-1 subscription for insured patients

The tradeoffs

  • No fixed medication price exists anywhere on the site — actual drug cost depends entirely on the patient's own insurance and pharmacy, so it cannot be compared apples-to-apples against competitors with a published price
  • Uninsured or underinsured patients could pay full retail branded-drug price (often $1,000+/month) with no compounded fallback offered here
Visit Call-On-Doc

Full Call-On-Doc review →

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons